Journal des rapports de cas cliniques

The Treatment Challenge of Vulvovaginal Candida glabrata: A Case Report

Abstract

Sarah Knoeckel

Vulvovaginal Candida glabrata is more challenging to treat than Candida albicans because of antifungal drug resistance. A 48-year-old woman with an ongoing complaint of vaginal irritation, pain, itching, and dyspareunia sought medical care multiple times over the course of two years with her primary care provider, gynecology and urology due to vulvovaginal Candida glabrata. She was treated with intravaginal boric acid, low dose vaginal estrogen cream, oral fluconazole, amphotericin-B vaginal tablets and oral oteseconazole, but found none of these treatments effective. Finally, she was treated with amphotericin B (100 mg) and flucytosine (1000 mg) formulated in a vaginal cream. Her symptoms resolved, and she tested negative. In conclusion, recurrent resistant vulvovaginal Candida glabrata is clinical challenging to treat, and for this woman led to her feeling frustrated and hopeless over these two years until a successful treatment was found.